SAN DIEGO, March 2, 2017 /PRNewswire/ -- GenomeDx Biosciences today announced the initiation of a prospective, randomized controlled trial evaluating the utility of its Decipher® Prostate Cancer Classifier, a commercially available genomic test that examines the activity of genes in prostate cancer cells and estimates the likelihood that a patient’s cancer will metastasize. Known as the Genomics in Michigan Impacting Observation or Radiation (G-MINOR) trial, this study is being conducted by the Michigan Urological Surgery Improvement Collaborative (MUSIC). MUSIC is a physician-led quality improvement collaborative comprised of a consortium of urology practices created through funding from Blue Cross Blue Shield of Michigan (BCBSM), a private health insurer.
While adding radiation treatment after prostate surgery is often considered for men with prostate cancer who are at high risk of recurrence, it is rarely used. G-MINOR’s primary endpoint is to determine the degree to which Decipher may help determine if additional treatment is needed. In addition, the results from G-MINOR will further populate GenomeDx’s genomic expression database, Decipher GRID®. The genomic information may be useful in the possible discovery of genes that help in diagnosing, preventing or treating prostate cancer in order to improve the level of patient care.
“This is a highly innovative trial, in terms of both its design and in the physician-led approach, which we believe will improve prostate cancer care in the state of Michigan. We are grateful for our partnership with BCBSM for their support of MUSIC, and for GenomeDx for its support of this trial,” said Todd Morgan MD, associate professor of urology at the University of Michigan and co-Principal Investigator of the G-MINOR trial. “The marriage of the MUSIC consortium with genomics provided by Decipher GRID may lead to further research that will ultimately benefit patients with prostate cancer in our state and beyond.”
GenomeDx is sponsoring Decipher Post-Op and GRID for all patients who choose to enroll in G-MINOR, which is open to men with a high risk of cancer recurrence who have undergone a radical prostatectomy within the past year at a participating MUSIC site in the state of Michigan.
“The use of Decipher can provide patients and physicians with a more accurate classification of tumor aggressiveness, compared to clinical measures alone,” said Doug Dolginow, M.D., chief executive officer of GenomeDx. “We believe G-MINOR is the first prospective randomized trial of a genomic biomarker in prostate cancer, and that the trial, coupled with our GRID genome-wide approach, will reveal important population-level insights that will drive further efforts towards addressing this disease.”
About Decipher GRID® and Decipher® Prostate Cancer Classifier Tests
GenomeDx’s Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx’s Decipher Prostate Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
More information is available at www.deciphertest.com and www.deciphergrid.com.
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx’s Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedx-biosciences-announces-initiation-by-michigan-urological-surgery-improvement-collaborative-music-of-prospective-randomized-clinical-study-of-decipher-300416694.html
SOURCE GenomeDx Biosciences
